

# Saro H Armenian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8428256/publications.pdf>

Version: 2024-02-01

142  
papers

7,023  
citations

61984

43  
h-index

64796

79  
g-index

153  
all docs

153  
docs citations

153  
times ranked

7130  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neighborhood disadvantage, health status, and health care utilization after blood or marrow transplant: BMTSS report. <i>Blood Advances</i> , 2023, 7, 293-301.	5.2	2
2	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	2.2	213
3	Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. <i>Cancer</i> , 2022, 128, 788-796.	4.1	29
4	Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 536-542.	2.5	9
5	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
6	Southern California Pediatric and Adolescent Cancer Survivorship (SC-PACS): Establishing a Multi-Institutional Childhood, Adolescent, and Young Adult Cancer Survivorship Consortium in Southern California. <i>Cureus</i> , 2022, 14, e21981.	0.5	1
7	Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. <i>Circulation Research</i> , 2022, 130, 632-651.	4.5	29
8	Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 157.e1-157.e9.	1.2	0
9	Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. <i>Blood</i> , 2022, 139, 3605-3616.	1.4	46
10	Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 1991-2003.	1.6	11
11	Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report. <i>Blood Advances</i> , 2022, 6, 2471-2479.	5.2	3
12	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1220-1226.	1.3	2
13	Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 367.e1-367.e9.	1.2	4
14	An integrated approach to cardioprotection in lymphomas. <i>Lancet Haematology</i> , the, 2022, 9, e445-e454.	4.6	5
15	Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12042-12042.	1.6	2
16	Association Between Body Composition and Development of Glucose Intolerance after Allogeneic Hematopoietic Cell Transplantation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 2004-2010.	2.5	3
17	Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trial. <i>Journal of Cancer Survivorship</i> , 2021, 15, 554-563.	2.9	17
18	Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 3-15.	1.3	35

#	ARTICLE	IF	CITATIONS
19	Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 726-729.	2.4	1
20	Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study. <i>Cancer</i> , 2021, 127, 794-800.	4.1	7
21	A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 967-974.	7.0	12
22	Reactivation of human herpesvirus 6 in pediatric allogeneic hematopoietic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13453.	1.7	3
23	Challenges associated with retrospective analysis of left ventricular function using clinical echocardiograms from a multicenter research study. <i>Echocardiography</i> , 2021, 38, 296-303.	0.9	5
24	Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 902-910.	1.6	15
25	Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors. <i>Cancer Medicine</i> , 2021, 10, 2956-2966.	2.8	6
26	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 125.	6.2	2
27	Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. <i>Blood Advances</i> , 2021, 5, 4102-4111.	5.2	10
28	Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation Survivors. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2073-2076.e5.	0.7	1
29	Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades. <i>JAMA Oncology</i> , 2021, 7, 1626.	7.1	33
30	Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation—A Blood or Marrow Transplant Survivor Study Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 840.e1-840.e7.	1.2	2
31	Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 755-764.	4.9	7
32	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 292-299.	2.0	13
33	Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1662-1664.	2.4	5
34	Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28702.	1.5	25
35	Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3161-3174.	1.6	95
36	Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH). <i>BMC Cancer</i> , 2020, 20, 721.	2.6	1

#	ARTICLE	IF	CITATIONS
37	Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3851-3862.	1.6	25
38	Atlas-based measures of left ventricular shape may improve characterization of adverse remodeling in anthracycline-exposed childhood cancer survivors: a cross-sectional imaging study. <i>Cardio-Oncology</i> , 2020, 6, 13.	1.7	1
39	Cardiovascular Health during and after Cancer Therapy. <i>Cancers</i> , 2020, 12, 3737.	3.7	14
40	Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study. <i>Cancer</i> , 2020, 126, 3322-3329.	4.1	7
41	Feasibility and Acceptability of Using a Telehealth Platform to Monitor Cardiovascular Risk Factors in Hematopoietic Cell Transplantation Survivors at Risk for Cardiovascular Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1233-1237.	2.0	13
42	Longitudinal Changes in Echocardiographic Parameters of Cardiac Function in Pediatric Cancer Survivors. <i>JACC: CardioOncology</i> , 2020, 2, 26-37.	4.0	24
43	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 962-972.	7.3	19
44	Cause-specific mortality in survivors of adolescent and young adult cancer. <i>Cancer</i> , 2020, 126, 2305-2316.	4.1	24
45	Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. <i>Journal of the American Heart Association</i> , 2020, 9, e014708.	3.7	94
46	Pain in older survivors of hematologic malignancies after blood or marrow transplantation: A BMTSS report. <i>Cancer</i> , 2020, 126, 2003-2012.	4.1	7
47	Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1153-1161.	6.3	20
48	NCCN Guidelines Insights: Survivorship, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1016-1023.	4.9	64
49	Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1105-1123.	4.9	9
50	Persistent Musculoskeletal Deficits in Pediatric, Adolescent and Young Adult Survivors of Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 794-803.	2.8	2
51	Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. <i>Cancer</i> , 2019, 125, 4033-4042.	4.1	3
52	Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma. <i>Open Heart</i> , 2019, 6, e001025.	2.3	10
53	Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2261-2266.	2.0	9
54	Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation. <i>Cancer</i> , 2019, 125, 4498-4508.	4.1	9

#	ARTICLE	IF	CITATIONS
55	Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2517-2521.	2.0	19
56	The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. <i>JACC: CardioOncology</i> , 2019, 1, 105-113.	4.0	17
57	Premature Aging in Young Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2019, 111, 226-232.	6.3	61
58	Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. <i>Cancer</i> , 2019, 125, 2762-2771.	4.1	10
59	Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study. <i>British Journal of Haematology</i> , 2019, 186, 367-370.	2.5	6
60	Optimizing Cardiovascular Care in Children With Acute Myeloid Leukemia to Improve Cancer-Related Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 1-6.	1.6	28
61	Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. <i>Cardiovascular Research</i> , 2019, 115, 922-934.	3.8	77
62	Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2019, 111, 837-844.	6.3	46
63	Cardiovascular events in cancer survivors. <i>Seminars in Oncology</i> , 2019, 46, 426-432.	2.2	8
64	Late Mortality after Allogeneic Bone Marrow Transplantation in Childhood for Bone Marrow Failure Syndromes and Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 749-755.	2.0	3
65	Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 328-334.	2.0	9
66	NCCN Guidelines Insights: Survivorship, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 784-794.	4.9	65
67	Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report. <i>Blood</i> , 2018, 131, 2720-2729.	1.4	10
68	Health equity for displaced children with cancer in the Middle East. <i>Cancer</i> , 2018, 124, 1322-1325.	4.1	2
69	A pediatric-type follicular lymphoma with marginal zone and monotypic intracytoplasmic plasmacytic differentiation. <i>Human Pathology: Case Reports</i> , 2018, 11, 25-31.	0.2	1
70	Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. <i>Cancer</i> , 2018, 124, 850-857.	4.1	14
71	Optimization of Health and Extension of Lifespan Through Childhood Cancer Survivorship Research. <i>Journal of Clinical Oncology</i> , 2018, 36, 2133-2134.	1.6	9
72	Predicting and Preventing Anthracycline-Related Cardiotoxicity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 3-12.	3.8	84

#	ARTICLE	IF	CITATIONS
73	Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. <i>Journal of Clinical Oncology</i> , 2018, 36, 2135-2144.	1.6	139
74	Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. <i>Blood Advances</i> , 2018, 2, 1756-1764.	5.2	53
75	Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 211-218.	4.9	12
76	Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2. <i>Leukemia</i> , 2018, 32, 2706-2709.	7.2	2
77	Accuracy of a Novel Handheld Wireless Platform for Detection of Cardiac Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3119-3125.	7.0	20
78	Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood. <i>JAMA Oncology</i> , 2018, 4, e182453.	7.1	27
79	Aging in a Relativistic Biological Space-Time. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 55.	3.7	4
80	Association of Exercise With Mortality in Adult Survivors of Childhood Cancer. <i>JAMA Oncology</i> , 2018, 4, 1352.	7.1	103
81	Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 700-705.	2.0	27
82	Cardiac Dysfunction and Heart Failure in Hematopoietic Cell Transplantation Survivors. <i>Heart Failure Clinics</i> , 2017, 13, 337-345.	2.1	10
83	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 893-911.	1.6	860
84	How I monitor long-term and late effects after blood or marrow transplantation. <i>Blood</i> , 2017, 130, 1302-1314.	1.4	52
85	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 201-210.	2.0	79
86	Biology of premature ageing in survivors of cancer. <i>ESMO Open</i> , 2017, 2, e000250.	4.5	148
87	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 270-275.	2.5	85
88	Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 738-738.	1.4	5
89	Decline in Late Mortality after Allogeneic Blood or Marrow Transplantation (alloBMT) Performed in Childhood: a Report from the BMT Survivor Study-2 (BMTSS-2). <i>Blood</i> , 2017, 130, 672-672.	1.4	0
90	Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1626-1633.	1.6	133

#	ARTICLE	IF	CITATIONS
91	Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. BMC Cardiovascular Disorders, 2016, 16, 187.	1.7	32
92	Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients. JAMA Oncology, 2016, 2, 1277.	7.1	93
93	CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study. Journal of Clinical Oncology, 2016, 34, 863-870.	1.6	102
94	Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Critical Reviews in Oncology/Hematology, 2016, 98, 222-234.	4.4	38
95	Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. Journal of Clinical Oncology, 2016, 34, 1122-1130.	1.6	376
96	Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biology of Blood and Marrow Transplantation, 2016, 22, 782-795.	2.0	155
97	Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future. Current Oncology Reports, 2016, 18, 22.	4.0	7
98	Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. Journal of Clinical Oncology, 2016, 34, 854-862.	1.6	154
99	Screening for Anthracycline-Related Cardiac Dysfunction in Childhood Cancer Survivors: Can Less be More?. Pediatric Blood and Cancer, 2015, 62, 2067-2068.	1.5	3
100	Approaches to Reduce the Long-Term Burden of Treatment-Related Complications in Survivors of Childhood Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 196-204.	3.8	13
101	Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2015, 16, e123-e136.	10.7	453
102	Long-Term Pulmonary Function in Survivors of Childhood Cancer. Journal of Clinical Oncology, 2015, 33, 1592-1600.	1.6	52
103	Collaborative Research in Childhood Cancer Survivorship: The Current Landscape. Journal of Clinical Oncology, 2015, 33, 3055-3064.	1.6	77
104	Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2015, 33, 2639-2645.	1.6	76
105	Screening and intervention for treatment-related cardiac dysfunction in childhood cancer survivors. Future Oncology, 2015, 11, 2031-2034.	2.4	1
106	Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. Blood, 2015, 126, 519-519.	1.4	9
107	Physiologic Frailty Among Hematopoietic Cell Transplantation (HCT) Survivors Suggests Accelerated Aging and Is a Predictor for Premature Mortality: A Report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood, 2015, 126, 739-739.	1.4	26
108	CELF4 variant and Anthracycline-related Cardiomyopathy (anth-card) - A COG Study (ALTE03N1).. Journal of Clinical Oncology, 2015, 33, 10066-10066.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Screening for Cardiac Dysfunction in Anthracycline-Exposed Childhood Cancer Survivors. <i>Clinical Cancer Research</i> , 2014, 20, 6314-6323.	7.0	61
110	Improving Screening Practices in Childhood Cancer Survivors at Risk for Treatment-Related Heart Failure. <i>Journal of Clinical Oncology</i> , 2014, 32, 3923-3925.	1.6	2
111	Carnitine and Cardiac Dysfunction in Childhood Cancer Survivors Treated with Anthracyclines. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1109-1114.	2.5	17
112	Cardiovascular disease in survivors of hematopoietic cell transplantation. <i>Cancer</i> , 2014, 120, 469-479.	4.1	64
113	Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 647-653.	1.6	122
114	Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors at Risk for Treatment-Related Heart Failure. <i>Annals of Internal Medicine</i> , 2014, 160, 672.	3.9	100
115	Burden of Morbidity in 10+ Year Survivors of Hematopoietic Cell Transplantation: Report from the Bone Marrow Transplantation Survivor Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1073-1080.	2.0	101
116	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2013, 163, 205-213.	2.5	94
117	Children's Oncology Group's 2013 blueprint for research: Survivorship and outcomes. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1063-1068.	1.5	65
118	Childhood cancer survivorship. <i>Current Opinion in Pediatrics</i> , 2013, 25, 16-22.	2.0	45
119	A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: A report from the international late effects of Childhood Cancer Guideline Harmonization Group. <i>Pediatric Blood and Cancer</i> , 2013, 60, 543-549.	1.5	275
120	Strategies to Prevent Anthracycline-Related Congestive Heart Failure in Survivors of Childhood Cancer. <i>Cardiology Research and Practice</i> , 2012, 2012, 1-8.	1.1	23
121	Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. <i>Blood</i> , 2012, 120, 4505-4512.	1.4	168
122	Yield of Screening for Long-Term Complications Using the Children's Oncology Group Long-Term Follow-Up Guidelines. <i>Journal of Clinical Oncology</i> , 2012, 30, 4401-4408.	1.6	92
123	Efficacy of the Children's Oncology Group (COG) long-term follow-up (LTFU) guidelines in reducing risk of congestive heart failure (CHF) in childhood cancer survivors (CCS). <i>Journal of Clinical Oncology</i> , 2012, 30, 9505-9505.	1.6	3
124	National Cancer Institute-National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Long-Term Organ Damage and Dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1573-1584.	2.0	76
125	Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 6023-6029.	1.4	136
126	Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). <i>Blood</i> , 2011, 118, 1413-1420.	1.4	176



#	ARTICLE	IF	CITATIONS
127	Ethnic differences in chronic health conditions after hematopoietic cell transplantation. <i>Cancer</i> , 2010, 116, 4152-4159.	4.1	4
128	Predictors of Late Cardiovascular Complications in Survivors of Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1138-1144.	2.0	85
129	Chronic Health Conditions in Childhood Cancer Survivors: Is it All Treatment-Related or Do Genetics Play a Role?. <i>Journal of General Internal Medicine</i> , 2009, 24, 395-400.	2.6	20
130	Prospective Monitoring for Invasive Aspergillosis Using Galactomannan and Polymerase Chain Reaction in High Risk Pediatric Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 920-926.	0.6	43
131	Late Cardiovascular Events in Survivors of Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2009, 114, 2252-2252.	1.4	0
132	Management of retinoblastoma with proximal optic nerve enhancement on MRI at diagnosis. <i>Pediatric Blood and Cancer</i> , 2008, 51, 479-484.	1.5	33
133	Late Congestive Heart Failure After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 5537-5543.	1.6	125
134	Cardiovascular disease after hematopoietic cell transplantation - lessons learned. <i>Haematologica</i> , 2008, 93, 1132-1136.	3.5	44
135	Differential Morbidity by Ethnicity in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS). <i>Blood</i> , 2008, 112, 454-454.	1.4	0
136	Evaluation of persistent pulmonary infiltrates in pediatric oncology patients. <i>Pediatric Blood and Cancer</i> , 2007, 48, 165-172.	1.5	22
137	Invasive diagnostic procedures for pulmonary infiltrates in pediatric hematopoietic stem cell transplant recipients. <i>Pediatric Transplantation</i> , 2007, 11, 736-742.	1.0	10
138	SAFETY AND IMMUNOGENICITY OF LIVE VARICELLA VIRUS VACCINE IN CHILDREN WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 368-370.	2.0	31
139	Risk Factors for Mortality Resulting From Bloodstream Infections in a Pediatric Intensive Care Unit. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 309-314.	2.0	36
140	Clinical heart failure in children, adolescents and young adults treated with anthracyclines and/or irradiation involving the heart region. <i>The Cochrane Library</i> , 0, , .	2.8	1
141	Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	7
142	Leveraging clinical trial populations and data from the Children's Oncology Group for cancer survivorship research. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	2.5	0